Ichnos Glenmark Files IND for ISB 2301 Cancer Drug

The New York biotech has submitted an FDA application for a pentaspecific immune cell activator aimed at solid tumours.

Updated on Nov. 22, 2026 in Biotech

Ichnos Glenmark Files IND for ISB 2301 Cancer Drug

Ichnos Glenmark Innovation has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ISB 2301, a pentaspecific immune cell activator designed to recognise three tumour-associated antigens. The company plans to begin a Phase 1 clinical trial in patients with solid tumours in 2027.

Why it matters

The IND submission moves ISB 2301 a step closer to human testing, which is the stage where safety and early anti-tumour activity are first assessed. The approach targets biological differences within solid tumours and the mechanisms those tumours use to suppress immune responses.

The figures are drawn from the company's preclinical design, with ISB 2301 combining five binding specificities and recognising three tumour-associated antigens while engaging T cells and NK cells. Efficacy and safety in humans have not yet been evaluated, and the FDA's decision on the IND is pending.

The players

Ichnos Glenmark Innovation

A clinical-stage biotechnology company headquartered in New York that develops multispecific immune-engaging therapies.

U.S. Food and Drug Administration

The federal agency that reviews Investigational New Drug applications and oversees the approval of new drugs in the United States.

The details

ISB 2301 was developed using the BEAT Multispecific Platform and incorporates antibody-dependent cellular cytotoxicity, checkpoint inhibition, and induction of a sustained type 1 immune response. In non-human primates it showed favourable pharmacokinetic and tolerability profiles, and the company's related candidate ISB 2001 has shown anti-tumour activity in an investigational Phase 1 study for relapsed or refractory multiple myeloma.

Timeline

  1. 2026-11-22

    Ichnos Glenmark Innovation submits the IND application for ISB 2301 to the FDA.

  2. 2027: Planned start of the Phase 1 trial in patients with solid tumours.

Tech Race

ISB 2301 extends the multispecific engager approach that Ichnos Glenmark has pursued with ISB 2001 in multiple myeloma into solid tumours, where immune-engaging therapies have historically had less success. The filing places the company among developers pursuing multi-target immune cell activators as an alternative to single-target antibodies.

For patients with advanced solid tumours, the program could eventually offer a new investigational option if early trials show acceptable safety. Any clinical benefit remains years away, and the trial's enrollment and results will determine whether the candidate progresses further.

The takeaway

Multi-target immune therapies like ISB 2301 are being tested to overcome the defenses solid tumours use against the immune system. Readers should watch for FDA clearance and the results of the planned 2027 Phase 1 study before drawing conclusions about its promise.

What happens next

The Phase 1 clinical trial of ISB 2301 in patients with solid tumours is planned to begin in 2027.

Further reading

Explore more Biotech news and developments in the field.

Source note: This article includes information reported by Themachinemaker.